演題詳細

ポスター / Poster

ポスター 23 (Poster 23) :低悪性度B細胞リンパ腫:ベンダムスチン

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
瀧本 理修 (Rishu Takimoto):1
1:札幌医科大学医学部附属病院 腫瘍・血液内科
 
前へ戻る

Retrospective investigation of bendamustine therapy with rituximab at our department

演題番号 : PS-1-170

村上 晴郎 (Haruo Murakami):1、浦瀬 文明 (Fumiaki Urase):1、上田 宏次 (Koji Ueda):1、永禮 靖章 (Yasuaki Nagare):1、和田 裕介 (Yusuke Wada):1

1:Sakai Hospital Kinki University School of Medicine,Osaka,Japan

 

Introduction:Indolent lymphoma is a disease that is responsive to initial treatment but which recurs and is then unlikely to be cured. Bendamustine is a novel antineoplastic with a purine analog-like structure bound to an alkyl group. We report our retrospective investigation of the efficacy of bendamustine therapy in combination with rituximab BR therapy at our hospital. Method:Of 10 patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, 4 had follicular lymphoma (FL), 2 had mantle-cell lymphoma (MCL), and 4 had transform type from FL(Transform). Among these patients, 9 had relapsed lymphoma and 1 had refractory lymphoma. The clinical stages were as follows; stage I in 2 patients, stage II in 2 patients, stage III in 4 patients, and stage IV in 2 patients. Results:From those patients who received BR therapy with rituximab, 6 showed a CR (3 with FL, 2 with MCL, and 1 with Transform) and 2 showed a PR(1 with FL and 1 with DLBCL). Grade 3 or 4 lymphopenia and grade 2 nausea or vomiting were the adverse drug reactions noted; however, no serious infection was observed. Discussion:We investigated the efficacy of BR therapy with rituximab retrospectively at our hospital. Although the data was obtained from a small number of patients, the response rate was high. Some response was also observed after salvage chemotherapy in patients with Transform, although this response was weaker than that noted in indolent lymphoma patients. These results suggest that salvage chemotherapy could be used for elderly patients who are difficult to be treated with high-dose chemotherapy.

前へ戻る